CytoDyn Inc. (CYDY) News

CytoDyn Inc. (CYDY): $0.41

0.02 (+4.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYDY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 405

in industry

Filter CYDY News Items

CYDY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CYDY News Highlights

  • For CYDY, its 30 day story count is now at 21.
  • Over the past 25 days, the trend for CYDY's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about CYDY are DE, BIO and CMC.

Latest CYDY News From Around the Web

Below are the latest news stories about CytoDyn Inc that investors may wish to consider to help them evaluate CYDY as an investment opportunity.

CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report

Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission

Intrado Digital Media | August 13, 2021

CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest

VANCOUVER, Washington, August 05, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group" or the "Activist Group"). The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control

Yahoo | August 5, 2021

CytoDyn Receives Clearance from Brazils ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazils regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organ

Business Wire | August 3, 2021

CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

VANCOUVER, Washington, August 03, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organi

Yahoo | August 3, 2021

CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid

VANCOUVER, Washington, August 02, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group") were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the "Board").

Yahoo | August 2, 2021

CytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle

Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case appears to be closed. There is no ongoing investigation August looks to be packed with positive news catalysts CytoDyn Inc. (OTCMKTS: CYDY) has been going through a massive consolidation since March 30, [] The post CytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle appeared first on Insider Financial .

Insider Financial | July 31, 2021

CytoDyn Prepares Compelling Argument for Breakthrough Therapy Designation

CytoDyn Inc. (OTCMKTS: CYDY) released its Triple Negative Breast Cancer (TNBC) data in an 8-K filing yesterday, showcasing leronlimabs extremely promising future in cancers, especially TNBC. The data was compiled by Creatv Bio and plotted historical comparisons to chemotherapy versus the current standard of care (SOC) and Todelvy, the last drug approved in TNBC. This [] The post CytoDyn Prepares Compelling Argument for Breakthrough Therapy Designation appeared first on EmergingGrowth.com .

Emerging Growth | July 26, 2021

Massive shareholder group requires a board overhaul at pharma firm CytoDyn

Younger chemist working with chemical substances throughout scientific experiment in laboratory. skynesher | E+ | Getty Photographs Firm: CytoDyn Inc. (CYDY) Enterprise: CytoDyn is a late-stage biotechnology firm. The corporate focuses on growing remedies for a number of therapeutic indications based mostly on leronlimab, a novel humanized monoclonal antibody concentrating on the CCR5 receptor. Its [] The post Massive shareholder group requires a board overhaul at pharma firm CytoDyn appeared first on News For Forex .

News For Forex | July 24, 2021

CytoDyn to hold webcast on July 22 to discuss cancer, NASH, and COVID-19 trials

CytoDyn (CYDY) will host an investment community webcast on Thursday, July 22, 2021 at 4:00 pm ET. Management will provide a full discussion of the results from the recently reported data from the mTNBC trials, along with updates on cancer, COVID-19, and NASH trials, and the status of the resubmission...

Seeking Alpha | July 20, 2021

CytoDyns Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)

CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer (mTNBC) that were well beyond the parameters needed to achieve ultimate approval if looking at historical controls. They had a 450% increase in overall survival (OS) at the 12 month point. Since this was a [] The post CytoDyns Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD) appeared first on Insider Financial .

Insider Financial | July 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.3928 seconds.